砷，以三氧化砷的简单形式，目前在市场上用于治疗急性早幼粒细胞白血病。由于砷的多方面作用机制，它在其他类型的白血病中也显示出潜力，但由于对正常细胞的毒副作用，受到了阻碍。本研究旨在确定能够设计和开发肿瘤寄生肽配合物的砷是否可以针对特定癌症进行有针对性的靶向治疗。最终目标是实现对所得砷治疗药物的剂量减少和副作用减轻。在本文中，我们介绍了一类新型的As-肽配合物的合成、表征和稳定性研究，旨在治疗白血病。在最稳定的配合物的体外生物学研究中，显示出对白血病细胞的毒性比人血细胞高1000倍，表明有潜力进行体内研究。

Arsenic, in the simple form of arsenic trioxide, is currently marketed for the treatment of acute promyelocytic leukemia. Due to the multifaceted mechanisms of action of arsenic, it has also shown promise in other types of leukemias but is hindered by its toxic effects toward normal cells. This research has aimed to determine whether tumor-homing peptide complexes of arsenic can be designed and developed to strategically target specific cancers. The end goal is to achieve dose reduction and decreased side effects of the resultant arsenic therapeutic agent. In this article, we present the synthesis, characterization, and stability studies of a new class of As-peptide complexes designed to target leukemia. In vitro biological studies of the most stable complex show 1000 times greater toxicity toward leukemia cells over human blood cells, indicating potential for progression to in vivo studies.